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Neuroactive steroids may play a role in the pathophysiology of psychotic disorders, but few studies examined this issue. We
compared serum levels of cortisol, testosterone, dehydroepiandrosterone, and progesterone between a representative sample of first-
episode psychosis (FEP) patients and age- and gender-matched healthy subjects. Furthermore, we analyzed the associations between
neuroactive steroids levels and the severity of psychotic symptom dimensions. Male patients had lower levels of progesterone than
controls (𝑝 = 0.03). Progesterone levels were inversely associated with the severity of positive symptoms (𝑝 = 0.007). Consistent
with preclinical findings, results suggest that progesterone might have a role in the pathophysiology of psychotic disorders.
1. Introduction
Preliminary evidence points to a possible role of several neu-
roactive steroids in the pathophysiology of psychotic disor-
ders, but clinical evidence is still scarce. Neuroactive steroids
such as cortisol (CORT), progesterone (PROG), testosterone
(T), dehydroepiandrosterone (DHEA), and estrogens play an
important role in shaping the central nervous system (CNS)
structure and function throughout the lifespan [1]. Neuroac-
tive steroids modulate a wide array of functions in the brain,
spanning from the neurodevelopment to adult neurogenesis
[2] and cognition [3]. In adult life, they exert a significant
influence on the activity of several neurotransmitter systems
that are relevant to the pathophysiology of psychosis, such as
the dopaminergic [4], glutamatergic, andGABAergic systems
[5].
In the past years, most studies on the role of neuroactive
steroids in psychosis have focused on cortisol, which is the
main end product of the Hypothalamic-Pituitary-Adrenal
(HPA) axis. A large body of evidence is now available indi-
cating that the dysregulation of the HPA axis activity plays
a detrimental role in the vulnerability to and in the course
of psychotic disorders [6–8]. In addition, epidemiological
and neurobiological data suggest that the administration of
exogenous estrogens might alleviate psychotic symptoms in
patients with established schizophrenia of both genders [9,
10].
More recently, preclinical studies have provided hints that
other neuroactive steroids might be relevant to the patho-
physiology of psychosis and lead to possible therapeutical
applications.These includeDHEA,T, andPROG.Of note, the
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administration of DHEA [11], the modulation of androgen-
related pathways [12], and the administration of PROG [13–
15] exerted antipsychotic-like effects in animal models of
schizophrenia. Despite this promising preliminary evidence,
we still lack evidence on the status of neuroactive steroids
in patients with psychotic disorders. Few studies investigated
the circulating levels of PROG in patients with psychosis and
yielded conflicting results. Levels of PROG were higher than
[16], similar to [17–19], or lower than [20] those of healthy
controls. Similarly DHEA levels were found to be lower than,
higher than, or similar to controls [11], whereas levels of T
were lower [18, 21] or normal [16, 22]. Moreover, only few
studies examined if there were associations between these
hormone levels and the severity of psychopathology [23].
Notably, the interpretation of these findings needs to take into
account the confounding effects of pharmacological treat-
ments, of the illness progression and endocrine-metabolic
changes that occur in patients along the different stages of
the illness. This study aims to assess the circulating levels of
various neuroactive steroids, namely, CORT, DHEA, T, and
PROG, in a group of males and females at their first episode
of a psychosis and age- and gender-matched healthy controls,
while testing the presence of associations between hormone
levels and severity of psychotic symptoms.
2. Methods
2.1. Subjects. The study was conceived as an add-on to
the European Network of National Schizophrenia Networks
Studying Gene-Environment Interactions (EU-GEI) study
for the Bologna Centre, Italy [24].We approached all subjects
with FEPwhowere consecutively treated in themental health
services of the catchment area of the Bologna EU-GEI centre
between January 2011 and November 2013. Inclusion criteria
were age 18–64 and first episode of functional psychotic
illness. Once patient’s clinical conditions were stable to
provide informed consent, he/she was asked to participate
in our study and donate blood for additional hormonal level
analyses. Patients underwent clinical and physical examina-
tions including ECG and routine laboratory tests to exclude
physical illness.
Healthy controls were selected from a population that was
examined in a recent study, aimed at establishing normative
levels of circulating steroidal hormones [25]. Data regarding
sociodemographic, clinical characteristics and psychiatric
comorbidities were available from 416 healthy subjects aged
18–64 years, living in a nearby catchment area of the
cases. From this sample, we further excluded subjects who
were suffering from relevant physical disorders, including
endocrinological disorders, obesity (BMI > 30), psychiatric
illnesses, and substance abuse, and those who were taking
any medications. Those with clinically relevant depressive
symptoms (a score of 20 or higher at the Beck Depression
Inventory) were also excluded to avoid confounding effects
on HPA axis activity. This led to a subsample of 153 partici-
pants, from which we randomly selected age-, gender-, and
BMI-matched controls. The protocol was approved by the
local Ethics Committee, in accordance with the Declaration
of Helsinki.
2.2. Assessment. Patients with FEP were assessed by experi-
enced psychiatrists. Validation of the clinical diagnosis on
DSM-IV criteria was obtained by researchers trained in the
use of Operational Criteria (OPCRIT) [26]. During the same
week of the blood drawing, patients were evaluated for the
severity of their clinical symptoms using the positive and
negative syndrome scale (PANSS). From PANSS scores, the
values of five symptom dimensions (negative symptoms,
disorganization, positive symptoms, excitement, and anxi-
ety/depression) were calculated [27]. The DUP was assessed
using the Nottingham Onset Schedule [28]. Exposure to
antipsychotics (AP) was converted in chlorpromazine equiv-
alents, according to recent indications [29].
2.3. Hormone Assays. Five millilitres of blood was collected
between 0800 and 1000 from fasting subjects using Vac-
uette Z serum beads clot activator tubes (Greiner Bio-One,
Kremsmu¨nster, Austria). Subjects were asked to abstain from
physical activity, caffeine consumption, and smoking on the
morning of the assessment. Among females, the hormonal
sampling was carried out in the follicular phase of the
menstrual cycle for all subjects (range 5–12 days). Samples
were centrifugated at 2000×g for 10min at room temperature
and sera stored in 1.5mL polypropylene tubes at −20∘C
until analysis. The circulating levels of CORT, T, DHEA,
and PROG were assessed from serum by isotopic dilution-
liquid chromatography tandem mass spectrometry (ID-LC-
MS/MS), following the protocol described in a recent study
[25].
2.4. Data Analyses. First, the normality of data was assessed
using a Shapiro-Wilk test. Then, levels of hormones were
compared between cases and controls using a matched
paired 𝑡-test or Wilcoxon test as appropriate. We also ran
exploratory correlation analyses (Pearson’s 𝑟 or Spearman’s
rho, as appropriate) to examine the associations between
hormonal levels and other factors, including the severity
of symptoms. If significant associations were detected, we
subsequently adjusted for the severity of other symptom
dimensions in multiple linear regression models to account
for their potential confounding effect [7]. SPSS 15.0 was used
for all analyses.
3. Results
Among 47 patients who were approached, 32 subjects (17
males, 15 females) met inclusion criteria and accepted to take
part in the study. Table 1 reports data on participants’ charac-
teristics. Nine patients were hospitalized at themoment of the
hormonal evaluation; one was drug-naive, 6 were receiving
quetiapine, 9 were receiving risperidone, 8 were receiving
olanzapine, 2 were receiving aripiprazole, 5 were receiving
oral haloperidol, and 1 was receiving clozapine.
Males with FEP had lower levels of CORT (𝑝 = 0.03)
and PROG (𝑝 = 0.03) than healthy male controls, while
differences were not significant for levels of T (𝑝 = 0.74) and
for DHEA (𝑝 = 0.09). In contrast, we did not find significant
differences in hormonal levels between female patients and
female controls.
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Table 1: Comparison between cases and controls.
Males Females
Cases
(𝑛 = 17)
Controls
(𝑛 = 17) Statistics
a Cases
(𝑛 = 15)
Controls
(𝑛 = 15) Statistics
Age 29.5 ± 10.5 30.3 ± 10.5 𝐹 = 0.19,
𝑝 = 0.85
31.2 ± 7.1 32.2 ± 6.0 𝐹 = 0.42,
𝑝 = 0.68
BMI 23.7 ± 4.0 24.4 ± 3.3 𝐹 = 0.53,
𝑝 = 0.60
22.5 ± 3.6 23.1 ± 3.3 𝐹 = 0.44,
𝑝 = 0.66
Recent cannabis use, % 41.2 0 𝜒
2
= 8.82,
𝑝 = 0.003
26.7 0 𝜒
2
= 4.62,
𝑝 = 0.03
∗
DUP, weeks 119 (42–424) — 42 (14–90)
Days of AP treatment 62 (17–149) — 146 (27–179)
Mean daily dose of APb 376 (211–571) — 274 (83–323)
Diagnosis, %
Schizophrenia 35.3 — 33.3 —
Bipolar disorder 5.9 — 6.7 —
Major depression 11.8 — 6.7 —
Otherc 47.1 53.3 —
PANSS, total score 64.6 ± 17.2 — 64.1 ± 18.8
Hormonal levelsd
CORT 120.6 (40.7) 143.1 (38.2) 𝐹 = 2.36,
𝑝 = 0.03
∗
120 (100–158) 130 (77–138) 𝑧 = 0.34,
𝑝 = 0.73
T 5.30 (1.48) 5.12 (1.79) 𝐹 = 0.34,
𝑝 = 0.74
0.22 (0.16–0.28) 0.26 (0.18–0.32) 𝑧 = 0.68,
𝑝 = 0.50
DHEA 6.67 (3.73) 8.67 (5.82) 𝐹 = 1.83,
𝑝 = 0.09
3.93 (3.03–6.94) 5.68 (4.78–7.73) 𝑧 = 1.14,
𝑝 = 0.26
PROG 0.05 (0.03–0.10) 0.10 (0.08–0.12) 𝑧 = 2.15,
𝑝 = 0.03
∗
0.06 (0.03–0.42) 0.18 (0.09–0.43) 𝑧 = 1.19,
𝑝 = 0.23
aData are compared using the paired-samples 𝑡-test if normally distributed (mean ± standard deviation reported) or with the paired-samples Wilcoxon test
if skewed median (interquartile range reported); bchlorpromazine equivalents; c includes brief psychotic disorder, psychotic disorder not otherwise specified,
and delusional disorder; dunit of measure: nmol/L.
BMI: bodymass index;DUP: duration of untreated psychosis; AP: antipsychotics; PANSS: positive and negative syndrome scale; CORT: cortisol; T: testosterone;
DHEA: dehydroepiandrosterone; PROG: progesterone.
∗
𝑝 < 0.05.
In exploratory analyses, we did not find significant corre-
lations between the hormonal levels and the cumulative dose
of AP treatment, the duration of AP treatment, and its mean
daily dose, except for T (daily dose: 𝑟 = 0.40, 𝑝 = 0.02).
Also, recent use of cannabis was not associated with the levels
of any neuroactive steroids in either gender or in the whole
sample.
Regarding the associationwith clinical symptoms, among
males, the levels of PROG were inversely associated with
the severity of positive symptoms (Spearman’s rho = −0.67,
𝑝 = 0.007) but not with other symptom dimensions (all 𝑝 >
0.18).This association held after adjusting for the other symp-
tom dimensions in linear regression (𝑝 = 0.02). Instead,
levels of CORT, DHEA, and T were not associated with the
severity of any symptomdimension. Among females, levels of
DHEA correlated positively with negative symptom dimen-
sion (𝑟 = 0.51, 𝑝 = 0.049) and disorganization (𝑟 = 0.56, 𝑝 =
0.03). Also, progesterone levels correlated with disorganiza-
tion (𝑟 = 0.59, 𝑝 = 0.02). However, none of these associations
remained statistically significant after adjusting for other
symptom dimensions in regression models.
4. Discussion
We found that male patients with first-episode psychosis
had lower levels of progesterone than those of age- and
gender-matched healthy controls. Furthermore, the levels
of progesterone correlated negatively with the severity of
positive symptoms, lending support to a possible role of this
hormone in the pathophysiology of psychotic disorders. To
our knowledge, this studywas the first to investigate the levels
of various neuroactive steroids among patients with a first
episode of psychotic illness, not restricted to schizophrenia,
and with a relatively low exposure to antipsychotics.
The evidence on progesterone levels in psychotic disor-
ders is still scarce; however our results are consistent with
those obtained in another study on male, antipsychotic-
naive patients with schizophrenia, during later episodes of
their illness [20]. Again, in another recent study on bipolar
disorder, males (but not females) who displayed positive
psychotic symptoms had lower levels of PROG compared
with those who did not [30]. Furthermore, data from the
former study showed that the levels of PROG tended to
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increase following treatment with AP, but they were still
lower than those of healthy controls at the end of follow-up
[20]. Nevertheless, other studies conducted on males with
schizophrenia, receiving antipsychotic treatment of longer
duration, did not find significant differences in PROG levels
with controls [17, 19, 31]. Consistently, the increase of the
adrenal production of progesterone induced by some AP
drugs (olanzapine and clozapine) was found to mediate part
of their pharmacological efficacy in animal models [32].
Taken together, these evidences support the view that lower
levels of PROG in males with psychotic disorders could
persist after initial antipsychotic drug therapy but normalize
in later stages of the illness.
Our results, instead, are in apparent contrast with those
of other studies finding elevated levels of both PROG and
CORT among antipsychotic-naive, acute-phase patients with
schizophrenia [16, 33]. However, Guest and colleagues did
not differentiate between genders; thus results cannot be
directly comparedwith ours. Also, PROG, similarly to CORT,
can display stress-related increases [34]; thus increases of
its levels might reflect state- rather than trait-related fluc-
tuations. In our study, in fact, CORT was also reduced in
male patients compared to controls, which could be due to
the measurement of the hormone during the stable phase
of the illness [7], especially after treatment with predom-
inantly second-generation agents [35]. Lastly, it must be
acknowledged that differences in the diagnostic composition
of the sample or other characteristics may also have played a
role.
Clearly, further studies are needed to corroborate and
extend these findings; however, they suggest that PROG levels
could be altered inmale patients with first-episode psychosis,
and this might contribute to a vulnerability towards positive
symptoms. Biological plausibility is based on several lines of
evidence: PROG can easily cross the blood-brain barrier and
exert anxiolytic and neuroprotective actions, mainly via its
conversion to the neurosteroid allopregnanolone and sub-
sequent interactions with several neurotransmitters systems,
including GABA and dopamine [34, 36]. Hence, a relative
deficiency of this hormone might increase the likelihood of
dysregulation in specific neurotransmitter systems that are
involved in the pathogenesis of psychotic symptoms [37, 38].
Conversely, preclinical evidence showed that the adminis-
tration of exogenous PROG could exert antipsychotic-like
effects [14, 15]. Lastly, recent evidence suggests that antipsy-
chotics benefits might depend on their anti-inflammatory role
[39]: interestingly, progesterone may share similar properties
[40]. Further research should clarify the status of PROG
in psychotic disorders, with the ultimate aim of possible
therapeutical applications [13].
To our knowledge, this was the first study investigating
the levels of PROG among patients with FEP, not limited to
the diagnosis of schizophrenia. We carefully matched a rep-
resentative sample of patients with FEP with healthy controls
andmeasured the hormone levels with a reliablemethod [25].
However, these findings should be considered as preliminary
and need further confirmation in light of some limitations.
First of all, the sample size was relatively small and clin-
ically heterogeneous and might have been underpowered
to detect meaningful associations. Also, the use of different
antipsychotic drugs or other subject characteristics may have
played a confounding role that at present we cannot rule
out. Nonetheless, the association between PROG levels and
positive symptoms held after adjusting for confounding
effects for other symptom dimensions. Second, we did not
measure prolactin levels. However, no patient showed signs
or symptoms of hyperprolactinemia at the time of the
exam, and previous studies showed no association between
progesterone and prolactin in males [19]. Third, we did not
control for smoking status, although cigarette smoking does
not seem to affect most of the hormones we analyzed [41].We
acknowledge that future studies should include this informa-
tion. Lastly, we have not corrected analyses for multiple com-
parisons, given the reduced sample size and pilot/exploratory
nature of this study.
5. Conclusions
In conclusion, we found that progesterone was reduced in
male but not female patients with a first episode of psychotic
disorders, and it was negatively correlated with the severity
of positive symptoms of psychosis. Whether it has a role in
the vulnerability to psychotic disorders or it is merely an
epiphenomenon of an altered stress response, it remains to
be settled; nonetheless extending the knowledge on the status
and role of PROG in psychosis might contribute to the study
of novel therapeutical applications.
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this article.
Acknowledgments
This is an independent study carried out thanks to the support
and the resources of the Department of Medical and Surgical
Sciences, Alma Mater Studiorum, University of Bologna,
Italy. The collaboration of Luigi Chiri as a researcher in this
study was possible thanks to the European Union Grant sup-
porting the EU-GEI study (European Community’s Seventh
Framework Program, Grant Agreement no. HEALTH-F2-
2009-241909, Project EU-GEI).
References
[1] B. S. McEwen, “Stress, sex, and neural adaptation to a changing
environment: mechanisms of neuronal remodeling,” Annals of
the New York Academy of Sciences, vol. 1204, supplement 1, pp.
E38–E59, 2010.
[2] N. Pluchino, M. Russo, A. N. Santoro, P. Litta, V. Cela, and A.
R. Genazzani, “Steroid hormones and BDNF,”Neuroscience, vol.
239, pp. 271–279, 2013.
[3] V. Birzniece, T. Ba¨ckstro¨m, I.-M. Johansson et al., “Neuroactive
steroid effects on cognitive functions with a focus on the
serotonin and GABA systems,” Brain Research Reviews, vol. 51,
no. 2, pp. 212–239, 2006.
[4] D. Sinclair, T. D. Purves-Tyson, K. M. Allen, and C. S.
Weickert, “Impacts of stress and sex hormones on dopamine
Schizophrenia Research and Treatment 5
neurotransmission in the adolescent brain,” Psychopharmacol-
ogy, vol. 231, no. 8, pp. 1581–1599, 2014.
[5] P. Zheng, “Neuroactive steroid regulation of neurotransmitter
release in the CNS: action, mechanism and possible signifi-
cance,”Progress inNeurobiology, vol. 89, no. 2, pp. 134–152, 2009.
[6] G. Aiello, M. Horowitz, N. Hepgul, C. M. Pariante, and V.Mon-
delli, “Stress abnormalities in individuals at risk for psychosis:
a review of studies in subjects with familial risk or with ‘ at
risk’ mental state,” Psychoneuroendocrinology, vol. 37, no. 10, pp.
1600–1613, 2012.
[7] M. Belvederi Murri, C. M. Pariante, P. Dazzan et al., “Hypo-
thalamic-pituitary-adrenal axis and clinical symptoms in first-
episode psychosis,” Psychoneuroendocrinology, vol. 37, no. 5, pp.
629–644, 2012.
[8] E. Walker, V. Mittal, and K. Tessner, “Stress and the hypotha-
lamic pituitary adrenal axis in the developmental course of
schizophrenia,”Annual Review of Clinical Psychology, vol. 4, pp.
189–216, 2008.
[9] J. Kulkarni, E. Gavrilidis, W. Wang et al., “Estradiol for
treatment-resistant schizophrenia: a large-scale randomized-
controlled trial in women of child-bearing age,” Molecular
Psychiatry, vol. 20, no. 6, pp. 695–702, 2015.
[10] J. Kulkarni, E. Gavrilidis, R. Worsley, T. V. Rheenen, and
E. Hayes, “The role of estrogen in the treatment of men
with schizophrenia,” International Journal of Endocrinology and
Metabolism, vol. 11, no. 3, pp. 129–136, 2013.
[11] M. S. Ritsner, “The clinical and therapeutic potentials of dehy-
droepiandrosterone and pregnenolone in schizophrenia,” Neu-
roscience, vol. 191, pp. 91–100, 2011.
[12] S. Paba, R. Frau, S. C. Godar, P. Devoto, F. Marrosu, and
M. Bortolato, “Steroid 5alpha-reductase as a novel therapeutic
target for schizophrenia and other neuropsychiatric disorders,”
Current Pharmaceutical Design, vol. 17, no. 2, pp. 151–167, 2011.
[13] G. Bristot, B. Ascoli, C. Gubert, B. Panizzutti, F. Kapczinski,
andA. R. Rosa, “Progesterone and itsmetabolites as therapeutic
targets in psychiatric disorders,” Expert Opinion onTherapeutic
Targets, vol. 18, no. 6, pp. 679–690, 2014.
[14] C. A. Frye and I. Sora, “Progesterone reduces hyperactivity of
female and male dopamine transporter knockout mice,” Behav-
ioural Brain Research, vol. 209, no. 1, pp. 59–65, 2010.
[15] R. Rupprecht, M. Koch, A. Montkowski et al., “Assessment of
neuroleptic-like properties of progesterone,” Psychopharmacol-
ogy, vol. 143, no. 1, pp. 29–38, 1999.
[16] P. C. Guest, E. Schwarz, D. Krishnamurthy et al., “Altered levels
of circulating insulin and other neuroendocrine hormones
associated with the onset of schizophrenia,” Psychoneuroen-
docrinology, vol. 36, no. 7, pp. 1092–1096, 2011.
[17] M. Beyazyu¨z, Y. Albayrak, E. Beyazyu¨z, C. U¨nsal, and E. Go¨ka,
“Increased serum dehydroepiandrosterone sulfate in the first
episode but not in subsequent episodes in male patients with
schizophrenia,”Neuropsychiatric Disease and Treatment, vol. 10,
pp. 687–693, 2014.
[18] T. J. Huber, C. Tettenborn, E. Leifke, and H. M. Emrich, “Sex
hormones in psychotic men,” Psychoneuroendocrinology, vol.
30, no. 1, pp. 111–114, 2005.
[19] M. Ritsner, A. Gibel, E. Ram, R. Maayan, and A. Weizman,
“Alterations in DHEA metabolism in schizophrenia: two-
month case-control study,” European Neuropsychopharmacol-
ogy, vol. 16, no. 2, pp. 137–146, 2006.
[20] M. Taherianfard and M. Shariaty, “Evaluation of serum steroid
hormones in schizophrenic patients,” Indian Journal of Medical
Sciences, vol. 58, no. 1, pp. 3–9, 2004.
[21] Y. Kaneda, “Possible relationship between testosterone and
comorbid major depressive episode in male patients with
schizophrenia treated with typical antipsychotic medications,”
Clinical Neuropharmacology, vol. 26, no. 6, pp. 291–293, 2003.
[22] E. Cˇesˇkova, R. Prˇikryl, and T. Kasˇpa´rek, “Testosterone in first-
episode schizophrenia,”Neuroendocrinology Letters, vol. 28, no.
6, pp. 811–814, 2007.
[23] M. Ritsner, A. Gibel, R. Maayan et al., “State and trait related
predictors of serum cortisol to DHEA(S) molar ratios and
hormone concentrations in schizophrenia patients,” European
Neuropsychopharmacology, vol. 17, no. 4, pp. 257–264, 2007.
[24] J. vanOs, B. P. Rutten, I.Myin-Germeys et al., “Identifying gene-
environment interactions in schizophrenia: contemporary chal-
lenges for integrated, large-scale investigations,” Schizophrenia
Bulletin, vol. 40, no. 4, pp. 729–736, 2014.
[25] F. Fanelli, I. Belluomo, V. D. Di Lallo et al., “Serum steroid pro-
filing by isotopic dilution-liquid chromatography-mass spec-
trometry: comparison with current immunoassays and refer-
ence intervals in healthy adults,” Steroids, vol. 76, no. 3, pp. 244–
253, 2011.
[26] P. McGuffin, A. Farmer, and I. Harvey, “A polydiagnostic appli-
cation of operational criteria in studies of psychotic illness.
Development and reliability of the OPCRIT system,” Archives
of General Psychiatry, vol. 48, no. 8, pp. 764–770, 1991.
[27] R. Emsley, J. Rabinowitz, M. Torreman et al., “The factor struc-
ture for the Positive and Negative Syndrome Scale (PANSS) in
recent-onset psychosis,” Schizophrenia Research, vol. 61, no. 1,
pp. 47–57, 2003.
[28] S. P. Singh, J. E. Cooper, H. L. Fisher et al., “Determining the
chronology and components of psychosis onset: The Notting-
ham Onset Schedule (NOS),” Schizophrenia Research, vol. 80,
no. 1, pp. 117–130, 2005.
[29] N. C. Andreasen, M. Pressler, P. Nopoulos, D. Miller, and B.-
C. Ho, “Antipsychotic dose equivalents and dose-years: a stand-
ardized method for comparing exposure to different drugs,”
Biological Psychiatry, vol. 67, no. 3, pp. 255–262, 2010.
[30] A. G. M. Johansson, P. Nikamo, M. Schalling, and M. Lande´n,
“Polymorphisms in AKR1C4 and HSD3B2 and differences in
serum DHEAS and progesterone are associated with paranoid
ideation during mania or hypomania in bipolar disorder,”
EuropeanNeuropsychopharmacology, vol. 22, no. 9, pp. 632–640,
2012.
[31] Y. Shirayama, K. Hashimoto, Y. Suzuki, and T. Higuchi, “Corre-
lation of plasma neurosteroid levels to the severity of negative
symptoms in male patients with schizophrenia,” Schizophrenia
Research, vol. 58, no. 1, pp. 69–74, 2002.
[32] C. E. Marx, M. J. VanDoren, G. E. Duncan, J. A. Lieberman,
and A. L. Morrow, “Olanzapine and clozapine increase the
GABAergic neuroactive steroid allopregnanolone in rodents,”
Neuropsychopharmacology, vol. 28, no. 1, pp. 1–13, 2003.
[33] M. Bicikova,M. Hill, D. Ripova, P.Mohr, and R. Hampl, “Deter-
mination of steroidmetabolome as a possible tool for laboratory
diagnosis of schizophrenia,” Journal of Steroid Biochemistry and
Molecular Biology, vol. 133, no. 1, pp. 77–83, 2013.
[34] M. Schumacher, C. Mattern, A. Ghoumari et al., “Revisiting
the roles of progesterone and allopregnanolone in the nervous
system: resurgence of the progesterone receptors,” Progress in
Neurobiology, vol. 113, pp. 6–39, 2014.
[35] S. Cohrs, C. Ro¨her,W. Jordan et al., “The atypical antipsychotics
olanzapine and quetiapine, but not haloperidol, reduce ACTH
and cortisol secretion in healthy subjects,” Psychopharmacology,
vol. 185, no. 1, pp. 11–18, 2006.
6 Schizophrenia Research and Treatment
[36] C. E. Marx, D. W. Bradford, R. M. Hamer et al., “Pregnenolone
as a novel therapeutic candidate in schizophrenia: emerging
preclinical and clinical evidence,”Neuroscience, vol. 191, pp. 78–
90, 2011.
[37] S. Kapur, “Psychosis as a state of aberrant salience: a frame-
work linking biology, phenomenology, and pharmacology in
schizophrenia,”TheAmerican Journal of Psychiatry, vol. 160, no.
1, pp. 13–23, 2003.
[38] A. D. Stan and D. A. Lewis, “Altered cortical GABA neurotrans-
mission in schizophrenia: insights into novel therapeutic strate-
gies,” Current Pharmaceutical Biotechnology, vol. 13, no. 8, pp.
1557–1562, 2012.
[39] L. Haring, K. Koido, V. Vasar et al., “Antipsychotic treatment
reduces psychotic symptoms and markers of low-grade inflam-
mation in first episode psychosis patients, but increases their
body mass index,” Schizophrenia Research, vol. 169, no. 1–3, pp.
22–29, 2015.
[40] S. Giatti, R. C.Melcangi, andM. Pesaresi, “The other side of pro-
gestins: effects in the brain,” Journal ofMolecular Endocrinology,
vol. 57, no. 2, pp. R109–R126, 2016.
[41] O. P. Soldin, K. H. Makambi, S. J. Soldin, and D. M. O’Mara,
“Steroid hormone levels associated with passive and active
smoking,” Steroids, vol. 76, no. 7, pp. 653–659, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
